GALDERMA demonstrates its continued commitment to innovation in dermatology with new data to be presented at EADV Congress 2022

0

ZUG, Switzerland–(BUSINESS WIRE)–Galderma has announced that it will present its latest scientific findings at the 31stSt Congress of the European Academy of Dermatology and Venereology (EADV) from September 7th to 10th, 2022 in Milan. This will include on-site clinical data presentations, a series of symposiums and booth activities, all focused on serving patients by offering options across the therapeutic dermatology, dermo-cosmetics and injectable aesthetics categories. As a leader in pure dermatology, Galderma’s significant presence at EADV reinforces its commitment to providing a truly innovative, science-based portfolio of world-class, cutting-edge brands and services.

The latest scientific findings presented by Galderma at EADV reflect the company’s significant investments in research and development with large studies across multiple indications for serious conditions such as prurigo nodularis, atopic dermatitis, acne, rosacea, non-melanoma skin cancer and onychomycosis. For over 40 years, Galderma has focused exclusively on dermatology and has proven to be one of the few players able to offer not only first-class product solutions, but also first-class solutions with new innovative modes of action. Today, Galderma is a leading scientific voice in these disease areas and remains committed to advancing advancements for patients with these and other serious skin conditions.

One of the company’s most anticipated news releases this year will focus on IL-31, a neuroimmune cytokine that has been shown to be a key mediator in prurigo nodularis and atopic dermatitis. The cytokine acts as a bridge between the immune and nervous systems and plays a crucial role in triggering and promoting the pathophysiological aspects including itching and inflammation1.2. Two symposia and eight scientific posters will examine the burden of disease, the role of IL-31 in these inflammatory skin diseases, and treatments under development.

Another focus of Galderma will be on sensitive skin, which affects a large segment of the population, with over 70% of women reporting suffering from its effects3. With a strong consumer skin range for sensitive skin including Cetaphil and the recent acquisition of Alastin Skincare, Galderma understands the need for specially designed treatments and personalized skincare regimens. At this year’s EADV, Galderma will join key opinion leaders to challenge the existing paradigms on sensitive skin and challenge the community on whether it should be considered a skin condition in its own right.

Other skin conditions that drive patients to their dermatologists include acne, rosacea, actinic keratosis and non-melanoma skin cancer, conditions affecting a significant cross-section of society. Galderma researches these conditions and has been bringing innovative products to patients and consumers for decades. At EADV, the company will present new data and host scientific meetings and discussions to explore novel patient-centric, holistic approaches in each of these areas to help identify the best personalized treatment regimens for each patient.

Galderma’s significant presence at EADV this year reflects its expertise in these common and often serious skin conditions and is a testament to its commitment to advancing dermatology for every skin story.

“We look forward to collaborating with the dermatology community at the

EADV Congress to exchange information, share insights and

Showcasing our latest developments and data spanning the spectrum

spectrum of dermatology. This reaffirms our ongoing commitment to

Understand and further develop the needs of patients and consumers

truly innovative dermatological solutions.”

BALDO SCASSELLATI SFORZOLINI, MD

GLOBAL HEAD OF RESEARCH & DEVELOPMENT, GALDERMA

Below is a full list of activities taking place.

Prurigo nodularis and atopic dermatitis

  • Thinking about neurodermatitis differently: It’s time for a new perspective – September 9, 1:00 p.m. – 2:00 p.m. CEST (Room: AMBER 3 and 4). Chaired by Professor Diamant Thaçi (Germany) and with Professor Marjolein de Bruin-Weller (Netherlands) and Professor Andreas Wollenberg (Germany)
  • Navigating through new data in prurigo nodularis: restoring hope to patients – September 10th, 13:00 – 14:00 CEST (Room: CORAL 6). Chaired by Professor Sonja Stehr (Germany) and Professor Giampiero Girolomoni (Italy) and with Professor Dr. Shawn Kwatra (USA) and Professor Dr. Bernhard Homey (Germany)

Sensitive skin

  • Simplifying sensitive skin: can we define it as a skin condition in its own right?September 7th, 13:00 – 14:00 CEST (Room: CORAL 6). Chaired by Professor Giovanni Pellacani (Italy) and with Professor Adam Friedman (USA) and Dr. Krzysztof Piotrowski (Switzerland)

acne

  • A novel, patient-centered approach to treating acne – September 8, 1:00 p.m. – 2:00 p.m. CEST (Room: CORAL 6). Co-chaired by Professor Alison Layton (UK) and Professor Doctor Jerry Tan (Canada) and with Dr. Vincenzo Bettoli (Italy)
  • Possibilities for a holistic approach to treating acne vulgaris – September 9, 9:15-10:00 CEST (Room: HUB 2.05). With Professor Brigitte Dreno (France), Professor Gabriella Fabbrocini and Doctor Magda Belmontesi (Italy)
  • Acne Update: Recent advances in the skin microbiome, C. acnes phylum co-residence, and best treatment practices – September 9th, 16:00 – 16:45 CEST (Room: HUB 2.08). With Professor Brigitte Dreno (France) and Professor Tami Lieberman (USA)

rosacea

  • Clinical challenges in rosacea: overcoming obstacles on the way to treatment optimization – September 8, 18:00 – 19:30 CEST (Room: CORAL 6). With Professor Doctor Giuseppe Micali (Italy), Professor Doctor Martin Schaller (Germany) and Professor Doctor Jerry Tan (Canada)

Actinic keratosis / melanoma skin cancer

  • An integrated approach to the treatment of actinic keratosis and nonmelanoma skin cancer – September 8, 2:30 p.m. – 3:15 p.m. CEST (Room: HUB 2.03). Chaired by Professor Merete Haedersdal (Denmark) and with Professor Claas Ulrich (Germany) and Doctor Magda Belmontesi (Italy)
  • Beyond the lesion: expert recommendations for patient-centered longitudinal management in actinic keratosis – September 9, 18:00 – 19:30 CEST (Room: AMBER 3 and 4). Co-chaired by Professor Rolf-Markus Szeimies (Germany) and Professor Colin Morton (UK) and with Professor Piergiacomo Calzavara-Pinton (Italy)
  • Personalization of actinic keratosis treatment (PAKT): expert recommendations to support patient-centered management of actinic keratosis (Lecture) – September 10, 10:15 a.m. CEST (Room: BROWN 2, FC05: Free Communication in Skin Oncology and Genetics). With Professor Rolf-Markus Szeimies (Germany)

onychomycosis

  • Onychomycosis update: Quantified penetration profile of topical amorolfine in infected human nails – September 8, 9:15 – 10:00 CEST (Room: HUB 2.01). With Professor Martin Schaller (Germany)

A wide range of new scientific data posters have been accepted for EADV this year and are available upon request.

About Galderma

Galderma is a leader in the pure dermatology category and is present in approximately 90 countries. We offer an innovative, science-backed portfolio of premium brands and services that span the spectrum of the fast-growing dermatology market through injectable aesthetics, dermocosmetics and therapeutic dermatology. Since our founding in 1981, we have dedicated our focus and passion to the largest organ in the human body – the skin – partnering with healthcare professionals to meet the unique needs of consumers and patients with outstanding results. Because we understand that the skin we are in shapes our lives, we advance dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience and Sculptra in injectable aesthetics; Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac and Loceryl in therapeutic dermatology; and Cetaphil and Alastin in dermocosmetics. For more informations: www.galderma.com.

references

1. Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis and pharmacological treatment of prurigo nodularis. Expert Rev. Clin Pharmakoi.2021;14(1):67-77. doi:10.1080/17512433.2021.1852080

2. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. doi:10.3389/fmed.2021.639097

3. Farage, Miranda A. “The Prevalence of Sensitive Skin.” US National Library of Medicine National Institutes of Health, www.ncbi.nlm.nih.gov/pmc/articles/PMC6533878.

Share.

Comments are closed.